SynthesisSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2015
Meta-analysis of incidence and risk of peripheral neuropathy associated with intravenous bortezomib.
Synthesis in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- Financial Burdens of Cancer Treatment: A Systematic Review of Risk Factors and Outcomes.Journal of the National Comprehensive Cancer Network : JNCCN · 2019Pooled it
- Efficacy and Safety of Panobinostat in Relapsed or/and Refractory Multiple Myeloma: Meta Analyses of Clinical Trials and Systematic Review.Scientific reports · 2016Pooled it
- A phase II trial of tamoxifen and bortezomib in patients with recurrent malignant gliomas.Journal of neuro-oncology · 2015Trial
- Neuronal metabolism role in ketogenic diet improvements in bortezomib-induced painful peripheral neuropathy mouse model.Pain reports · 2026Article
- Impact of blood pressure variability on the prediction of cancer therapy-related cardiovascular toxicity in patients with multiple myeloma.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- Blood pressure variability as predictor of cancer therapy-related cardiovascular toxicity in patients with Multiple Myeloma.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- Bortezomib-induced peripheral neuropathy: from molecular mechanisms to clinical management.Frontiers in pharmacology · 2025Review
- Bortezomib-induced neuropathy in multiple myeloma manifesting as foot drop due to peroneal nerve palsy.BMJ case reports · 2024Article
- Emerging Approaches for the Management of Chemotherapy-Induced Peripheral Neuropathy (CIPN): Therapeutic Potential of the C5a/C5aR Axis.Pain and therapy · 2022Review
- Chemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pathomechanisms and Treatment.Oncology and therapy · 2021Review
- Peripheral Neuropathy under Oncologic Therapies: A Literature Review on Pathogenetic Mechanisms.International journal of molecular sciences · 2021Review
- Vincristine- and bortezomib-induced neuropathies - from bedside to bench and back.Experimental neurology · 2021Review
- Prevalence of Chemotherapy-Induced Peripheral Neuropathy in Multiple Myeloma Patients and its Impact on Quality of Life: A Single Center Cross-Sectional Study.Frontiers in pharmacology · 2021Article
- Cell-Based Optimization of Covalent Reversible Ketoamide Inhibitors Bridging the Unprimed to the Primed Site of the Proteasome β5 Subunit.ChemMedChem · 2019Article
- Mechanisms of Chemotherapy-Induced Peripheral Neuropathy.International journal of molecular sciences · 2019Review
- Efficacy and safety of carfilzomib in relapsed and/or refractory multiple myeloma: systematic review and meta-analysis of 14 trials.Oncotarget · 2018Article
- Incidence and relative risk of peripheral neuropathy in cancer patients treated with eribulin: a meta-analysis.Oncotarget · 2017Article
- Update on Chemotherapy-Induced Peripheral Neuropathy.Current neurology and neuroscience reports · 2017Review
- Genetic Susceptibility to Bortezomib-Induced Peripheral Neuroropathy: Replication of the Reported Candidate Susceptibility Loci.Neurochemical research · 2017Article
- The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma.Expert opinion on drug discovery · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBortezomib is a proteasome inhibitor which has demonstrated activity against recurrent or newly diagnosed multiple myeloma (MM) and mantle cell lymphoma. Peripheral neuropathy has been described with this agent, although the overall incidence and relative risk remain unclear. We performed a meta-analysis to calculate the incidence of peripheral neuropathy associated with the use of intravenous bortezomib in MM and lymphoma and to compare the relative risk compared with placebo.
methodsWe searched PubMed, Embase, Cochrane databases, and meeting proceedings from the American Society of Clinical Oncology (ASCO) for relevant clinical trials. Eligible studies included prospective phase 2 and 3 clinical trials with toxicity profile on peripheral neuropathy associated with intravenous bortezomib in patients with MM and lymphoma. Statistical analyses were done to calculate summary incidences, relative risks (RRs), and 95 % confidence intervals (CIs), employing fixed- or random-effects models depending on the heterogeneity of the included studies.
resultsAltogether, 34 clinical trials were selected for the meta-analysis, yielding a total of 6492 patients. The incidence of peripheral neuropathy (all grades) was 33.9 % (95 % CI, 29.9-38.5 %) and that of high-grade events was 8.1 % (95 % CI, 6.9-9.4 %). The relative risks of bortezomib-induced peripheral neuropathy compared to placebo were increased for all-grade (RR = 4.89; 95 % CI, 2.52-9.51) and high-grade (RR = 4.53; 95 % CI, 2.04-10.07) peripheral neuropathy (for randomized controlled trials only). Our analysis was also stratified by different underlying diseases, and patients with lymphoma had an increased incidence of all-grade peripheral neuropathy than those with MM when treated with intravenous bortezomib.
conclusionsTreatment with intravenous bortezomib is associated with an increased risk of developing peripheral neuropathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.